Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers.
The productive cycle of human papillomaviruses (HPVs) can be divided into discrete phases. Cell proliferation and episomal maintenance in the lower epithelial layers are followed by genome amplification and the expression of capsid proteins. These events, which occur in all productive infections, can be distinguished by using antibodies to viral gene products or to surrogate markers of their expression. Here we have compared precancerous lesions caused by HPV type 16 (HPV16) with lesions caused by HPV types that are not generally associated with human cancer. These include HPV2 and HPV11, which are related to HPV16 (supergroup A), as well as HPV1 and HPV65, which are evolutionarily divergent (supergroups E and B). HPV16-induced low-grade squamous intraepithelial lesions (CIN1) are productive infections which resemble those caused by other HPV types. During progression to cancer, however, the activation of late events is delayed, and the thickness of the proliferative compartment is progressively increased. In many HPV16-induced high-grade squamous intraepithelial lesions (CIN3), late events are restricted to small areas close to the epithelial surface. Such heterogeneity in the organization of the productive cycle was seen only in lesions caused by HPV16 and was not apparent when lesions caused by other HPV types were compared. By contrast, the order in which events in the productive cycle were initiated was invariant and did not depend on the infecting HPV type or the severity of disease. The distribution of viral gene products in the infected cervix depends on the extent to which the virus can complete its productive cycle, which in turn reflects the severity of cervical neoplasia. It appears from our work that the presence of such proteins in cells at the epithelial surface allows the severity of the underlying disease to be predicted and that markers of viral gene expression may improve cervical screening.
Middleton
Kate
K
National Institute for Medical Research, Mill Hill, London.
Peh
Woei
W
Southern
Shirley
S
Griffin
Heather
H
Sotlar
Karl
K
Nakahara
Tomomi
T
El-Sherif
Amira
A
Morris
Lesley
L
Seth
Rashmi
R
Hibma
Merilyn
M
Jenkins
David
D
Lambert
Paul
P
Coleman
Nicholas
N
Doorbar
John
J
D015415:Biomarkers; D018450:Disease Progression; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000737:chemistry*; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis* / Q000821:virology*; D014764:Viral Proteins / Q000032:analysis*; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis* / Q000821:virology*
D015415:Biomarkers; D018809:Proliferating Cell Nuclear Antigen; D014764:Viral Proteins